This symposium will feature updated information on lymphoma biology, diagnosis, immunology, and genetics, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphomas. Faculty will review the current standard of care and present their own perspectives on how they treat various types of lymphomas. Participants will have the opportunity to discuss diagnostic and management cases, and how to incorporate biologic and genetic biomarkers into clinical practice and clinical trials.

The target audience for this symposium includes medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in the diagnosis, treatment, and biomedical research of lymphoma.

**Special Luncheon Events**
Participants are invited to attend the special luncheon events, one hosted by the Adult BMT Service and the other hosted by the Myeloma Service. Please RSVP for the luncheons during registration (space is limited and we do encourage early registration).

- **Adult BMT Luncheon** (Saturday, 12:00-1:00 PM)
- **Myeloma Luncheon** (Sunday, 12:00-1:00 PM)

Additional details will be announced soon.

**Networking Reception**
Participants are invited to a complimentary networking reception on Saturday evening, which will provide an opportunity to meet and interact with the course faculty and get to know other symposium attendees. Please RSVP for the reception during registration.

**Live Simulcast Available**
We are pleased to offer a live simulcast for this symposium, available to all non-MSK employees. CME credit is offered for the live simulcast and active participation is required throughout the course. We do hope you will attend in person but understand that can sometimes be a challenge, so we are happy to offer the live simulcast as an option.

Register online for the live simulcast: mskcc.org/LymphomaCourse
FACULTY

Invited Faculty

Christian Buske, MD
CCC Ulm/University Hospital Ulm
Ulm, Germany

Riccardo Dalla-Favera, MD
Columbia University
New York, NY

Martin Dreyling, MD, PhD
University of Munich
Munich, Germany

John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Queen Mary’s School of Medicine
University of London
London, United Kingdom

Michael Hallek, MD
Clinic I of Internal Medicine
University Hospital Cologne
Cologne, Germany

Alex Herrera, MD
City of Hope National Medical Center
Duarte, CA

Tim Illidge, BSc, PhD, FRCP, FRCR, FRCPath
University of Manchester
Manchester, United Kingdom

Ari M. Melnick, MD
Weill Cornell Medical College
New York, NY

Markus Müschen, MD, PhD
City of Hope National Medical Center
Duarte, CA

Christian Grommes, MD
Steven Horwitz, MD
Anthony Mato, MD, MSCE
David J. Straus, MD
Dana Tsui, PhD

Michael Reth, PhD
University of Freiburg
Freiburg, Germany

Jean-Ehrland Ricci, PhD
INSEERM
Nice, France

Davide Rossi, MD, PhD
Institute of Southern Switzerland IOSI
Bellinzona, Switzerland

Gilles Salles, MD, PhD
University of Lyon
Lyon, France

Bouthaina Shbib Dabaja, MD
MD Anderson Cancer Center
Houston, TX

Louis Staudt, MD, PhD
National Cancer Institute
Bethesda, MD

Karin Tarte, PhD
Rennes University Hospital
Rennes, France

Chi Van Dang, MD, PhD
University of Pennsylvania
Philadelphia, PA

Catherine Wu, MD
Dana-Farber Cancer Institute
Boston, MA

MSK Faculty

Faculty Disclosure
It is the policy of MSK to make every effort to ensure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

SCHEDULE

Saturday, May 2, 2020

7:30 AM  Registration and Breakfast
8:00 AM  Welcome and Opening Remarks  Anas Younes, MD

Pathology
MODERATOR: Ahmet Dogan, MD, PhD

8:05 AM  Pathology Classification  Ahmet Dogan, MD, PhD
8:40 AM  Introduction and Clinical Application of ctDNA  Dana Tsui, PhD
9:10 AM  Discussion

Diffuse Large B Cell Lymphoma
MODERATOR: Anas Younes, MD

9:30 AM  Molecular Pathogenesis  Riccardo Dalla-Favera, MD
10:00 AM  Molecular Classification  Louis Staudt, MD, PhD
10:30 AM  The Tale of Ramos and the Function of CD20  Michael Reth, PhD
11:00 AM  Evolving Frontline and Salvage Therapy of DLBCL  Anas Younes, MD
11:30 AM  Discussion
12:00 PM  Lunch Break

Adult BMT Luncheon (Optional)
Additional details will be announced soon. Please RSVP for this luncheon during registration (space is limited and we do encourage early registration).

Chronic Lymphocytic Leukemia (CLL)
MODERATOR: Andrew D. Zelenetz, MD, PhD

1:00 PM  Pathogenesis  John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
1:30 PM  Current Management  Michael Hallek, MD
2:00 PM  Novel Treatment Approaches  Andrew D. Zelenetz, MD, PhD
2:30 PM  Real World Experience  Anthony Mato, MD, MSCE
3:00 PM  Discussion
3:20 PM  Break

Follicular Lymphoma
MODERATOR: Hans-Guido Wendel, MD

3:40 PM  Epigenetics  Ari M. Melnick, MD
4:00 PM  Role of the Microenvironment  Karin Tarte, PhD
4:20 PM  Targeting Serine Metabolism in Follicular Lymphoma  Hans-Guido Wendel, MD
4:40 PM  Therapy of FL  Gilles Salles, MD, PhD
5:10 PM  Discussion
5:30 PM  Adjourn

Networking Reception
Participants are invited to a complimentary networking reception from 5:30-6:30 pm in the lobby of Zuckerman Research Center. Hors d’oeuvres and refreshments will be served.
Sunday, May 3, 2020

7:30 AM  Breakfast

**Focus on Tumor Metabolism**

**MODERATOR:** Andrew Intlekofer, MD, PhD

8:00 AM  Introduction to Tumor Metabolism
Andrew Intlekofer, MD, PhD

8:10 AM  Metabolic Control of T Cell Lymphoma
Andrew Intlekofer, MD, PhD

8:30 AM  Metabolic Gatekeepers in B Cell Malignancies
Markus Müschen, MD, PhD

8:50 AM  Metabolism and Lymphoma: From Basic to Translational Research
Jean-Ehrland Ricci, PhD

9:10 AM  Mitochondrial Reprogramming and Resistance to BCL2 Inhibition in Lymphoid Malignancies
Catherine Wu, MD

9:30 AM  TBA
Chi Van Dang, MD, PhD

9:50 AM  Discussion

10:00 AM  Break

**How I Treat (Session I)**

**MODERATOR:** David J. Straus, MD

10:20 AM  MCL
Martin Dreyling, MD, PhD

10:40 AM  Marginal Zone: Molecular Pathogenesis and Treatment Approaches
Davide Rossi, MD, PhD

11:00 AM  Advanced Stage Hodgkin Lymphoma
David J. Straus, MD

11:20 AM  Relapsed HL
Alex Herrera, MD

11:40 AM  Discussion

12:00 PM  Lunch Break

**Myeloma Luncheon (Optional)**

Additional details will be announced soon. Please RSVP for this luncheon during registration (space is limited and we do encourage early registration).

**Novel Approaches in Radiation Therapy**

**MODERATOR:** Joachim Yahalom, MD, FACR

1:00 PM  Novel Radiation Therapy-based Combinations
Joachim Yahalom, MD, FACR

1:20 PM  Immunoradiotherapy
Tim Illidge, BSc, PhD, FRCPE, FRCR, FRCPath

1:40 PM  Proton Therapy in Lymphoma
Bouthaina Shbib Dabaja, MD

2:00 PM  Discussion

2:20 PM  Break

**How I Treat (Session II)**

**MODERATOR:** Ariela Noy, MD

2:40 PM  Waldenstrom
Christian Buske, MD

3:00 PM  Burkitt Lymphoma and HIV Lymphoma
Ariela Noy, MD

3:20 PM  T Cell Lymphoma
Steven Horwitz, MD

3:40 PM  Primary CNS Lymphoma
Christian Grommes, MD

4:00 PM  Discussion

4:30 PM  Closing Remarks
Anas Younes, MD

4:45 PM  Adjourn

---

**REGISTRATION**

**Registration Fees**

<table>
<thead>
<tr>
<th></th>
<th>Early Rate*</th>
<th>General</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs and DOs)</td>
<td>$350</td>
<td>$400</td>
</tr>
<tr>
<td>Nurses, PAs and Other Healthcare Professionals</td>
<td>$150</td>
<td>$200</td>
</tr>
<tr>
<td>Residents and Fellows</td>
<td>$100</td>
<td>$150</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$650</td>
<td>$700</td>
</tr>
<tr>
<td>Live Simulcast***</td>
<td>$550</td>
<td>$600</td>
</tr>
</tbody>
</table>

*Early registration rates available through March 7, 2020.
**Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.
***Please note that the live simulcast is only available to non-MSK employees. MSK employees are welcome to register to attend this course in person.

Register online: [mskcc.org/lymphomacourse](http://mskcc.org/lymphomacourse)

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

- MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

**Symposium Location**

Zuckerman Research Center
417 East 68th Street
New York, NY

MSK has negotiated special rates and amenities at select hotels in Manhattan. For more information, visit: [mskcc.org/lymphomacourse](http://mskcc.org/lymphomacourse)

**Accreditation**

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**AMA Credit Designation Statement**

MSK designates this live activity for a maximum of **16.75 AMA PRA Category 1 Credits™**. Physicians should claim only credit commensurate with the extent of their participation in the activity.

---

**Memorial Sloan Kettering Cancer Center**